Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Acquires $300,300.00 in Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Sheila Gujrathi bought 130,000 shares of Ventyx Biosciences stock in a transaction on Monday, December 23rd. The shares were acquired at an average price of $2.31 per share, for a total transaction of $300,300.00. Following the completion of the acquisition, the director now owns 130,000 shares of the company’s stock, valued at approximately $300,300. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Ventyx Biosciences Stock Performance

NASDAQ:VTYX opened at $2.38 on Friday. The stock has a 50-day simple moving average of $2.29 and a 200 day simple moving average of $2.31. Ventyx Biosciences, Inc. has a 52-week low of $1.67 and a 52-week high of $11.48. The company has a market cap of $168.29 million, a PE ratio of -1.01 and a beta of 0.48.

Hedge Funds Weigh In On Ventyx Biosciences

Several hedge funds have recently made changes to their positions in VTYX. JPMorgan Chase & Co. boosted its holdings in Ventyx Biosciences by 2.0% during the third quarter. JPMorgan Chase & Co. now owns 1,007,519 shares of the company’s stock worth $2,196,000 after purchasing an additional 20,236 shares during the last quarter. Barclays PLC boosted its stake in shares of Ventyx Biosciences by 273.1% during the 3rd quarter. Barclays PLC now owns 80,295 shares of the company’s stock worth $175,000 after buying an additional 58,776 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Ventyx Biosciences by 5.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company’s stock valued at $3,034,000 after acquiring an additional 77,350 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Ventyx Biosciences in the third quarter valued at about $246,000. Finally, State Street Corp raised its holdings in Ventyx Biosciences by 0.8% during the third quarter. State Street Corp now owns 1,187,650 shares of the company’s stock worth $2,589,000 after acquiring an additional 9,783 shares in the last quarter. 97.88% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. HC Wainwright reiterated a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Monday, November 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.